Bevacizumab, sold under the brand name Avastin, is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody used in combination with antineoplastic agents for the treatment of many types of cancer. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth. Bevacizumab inhibits angiogenesis by binding to and neutralizing VEGF-A.
Bevacizumab Biosimilar Antibody
$205.00 – $2,500.00
Bevacizumab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human vascular endothelial growth factor A (VEGF-A) protein.
Host/Isotype: Human/IgG1
Class: Monoclonal
Immunogen: Human VEGF-A protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.